Categories AlphaGraphs, Earnings, Retail

Colgate-Palmolive’s stock tanks despite Q4 results beat

Colgate-Palmolive Company (CL) reported better-than-expected revenue and earnings for the fourth quarter of 2018 but shares fell 3.2% in premarket hours on Friday.

Worldwide net sales declined 2% year-over-year to $3.81 billion while organic sales grew 2%. Global unit volume rose 0.5%. The professional skin care acquisitions contributed 1% to net sales and unit volume growth during the quarter.

Colgate-Palmolive fourth quarter 2018 earnings infographic
Colgate-Palmolive Q4 2018 Earnings Infographic

On a GAAP basis, net income was $606 million or $0.70 per share compared to $323 million or $0.37 per share in the prior-year quarter. Last year’s earnings results were impacted by higher aftertax charges from the Global Growth and Efficiency Program and a charge of $275 million related to the US tax reform.

On an adjusted basis, net income dropped 3% to $638 million and diluted EPS fell 1% to $0.74 from the prior-year period.

Also see: Colgate-Palmolive Q4 2018 Earnings Conference Call Transcript

Colgate plans to increase investments in its brands, e-commerce capabilities and in its professional skin care businesses, Elta MD and PCA Skin. The company is also looking to expand its portfolio by rolling out its elmex and meridol brands into new markets.

Colgate-Palmolive sinks after revenues miss estimates

Colgate posted sales declines in all its regions except for North America which saw a growth of 5% in sales and 3% in unit volume. Net sales in the Hill’s Pet Nutrition segment grew 6% during the quarter.

For 2019, Colgate expects net sales to be flat to up low-single-digits, with organic sales growth of 2-4%. On a GAAP basis, based on current spot rates, the company expects to see gross margin expansion and a low-single-digit decline in EPS. Adjusted EPS is expected to decline in the mid-single-digit range.

 

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top